XML 27 R10.htm IDEA: XBRL DOCUMENT

Organization, Liquidity, and Capital Resources	9 Months Ended
Organization, Liquidity, and Capital Resources	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Liquidity, and Capital Resources	Organization, liquidity and capital resources Organization Arcus Biosciences, Inc. (referred to as "Arcus," "we," "our," "us," or the "Company") is a clinical-stage, biopharmaceutical company focused on creating best-in-class therapies. Using our robust and highly efficient drug discovery capability, we have created a significant portfolio of investigational products which are in clinical development, with our most advanced molecule, an anti-TIGIT antibody, now in four Phase 3 registrational studies targeting lung and gastrointestinal cancers. Our deep portfolio of novel small molecules and enabling antibodies allows us to create highly differentiated therapies, which we are developing to treat multiple large indications. We operate and manage our business as one reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients. Liquidity and Capital Resources As of September 30, 2023, we had cash, cash equivalents and marketable securities of $950 million, which we believe will be sufficient to fund our planned operations for a period of at least twelve months following the date of filing of this report.